BridgeBio Pharma reported positive top‑line results from a global Phase III trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1). The company said 76% of treated patients met prespecified serum and urine calcium targets at 24 weeks versus 4% on conventional therapy; a secondary analysis showed parathyroid hormone correction in 91% of treated patients. BridgeBio described the drug as well tolerated with safety consistent with ADH1 biology and noted plans to file for FDA review in 2026. Management highlighted that responders were off supplemental calcium and vitamin D. The readout strengthens BridgeBio’s rare‑disease franchise after recent positive data across multiple programs. For clinicians and payers, a successful approval could change standard of care for ADH1 and demonstrates how focused genetic‑disease programs can produce near‑term regulatory opportunities.